Stock Track | Catalyst Pharmaceuticals Soars 6.36% After Hours on Strong Q3 Results, Raised Guidance

Stock Track11-06

Shares of Catalyst Pharmaceuticals (CPRX) jumped 6.36% in after-hours trading on Wednesday following the company's release of better-than-expected third-quarter results and an increase in full-year guidance. The biopharmaceutical firm, which focuses on developing and commercializing therapies for people with rare diseases, demonstrated strong financial performance driven by its key products.

Catalyst reported Q3 revenue of $148.40 million, significantly beating analyst estimates of $136.80 million. The company's flagship product, FIRDAPSE, continued to show sustained organic growth and market penetration, while AGAMREE also contributed to the revenue growth with strong demand and penetration into Duchenne Muscular Dystrophy (DMD) centers. In light of these positive results, Catalyst raised its full-year 2025 revenue guidance to $565-$585 million, up from previous estimates.

The company's confidence in its future prospects was further underscored by the announcement of a $200 million share repurchase program. This move, coupled with the strong financial results and raised guidance, signals management's optimistic outlook for Catalyst's continued growth. Investors responded positively to these developments, as reflected in the significant after-hours stock price increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179410063?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 06:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179410063","market":"nz","top_or_hot":-1,"title":"Stock Track | Catalyst Pharmaceuticals Soars 6.36% After Hours on Strong Q3 Results, Raised Guidance","media":"Stock Track","content":"<p>Shares of Catalyst Pharmaceuticals (CPRX) jumped 6.36% in after-hours trading on Wednesday following the company's release of better-than-expected third-quarter results and an increase in full-year guidance. The biopharmaceutical firm, which focuses on developing and commercializing therapies for people with rare diseases, demonstrated strong financial performance driven by its key products.</p>\n\n<p>Catalyst reported Q3 revenue of $148.40 million, significantly beating analyst estimates of $136.80 million. The company's flagship product, FIRDAPSE, continued to show sustained organic growth and market penetration, while AGAMREE also contributed to the revenue growth with strong demand and penetration into Duchenne Muscular Dystrophy (DMD) centers. In light of these positive results, Catalyst raised its full-year 2025 revenue guidance to $565-$585 million, up from previous estimates.</p>\n\n<p>The company's confidence in its future prospects was further underscored by the announcement of a $200 million share repurchase program. This move, coupled with the strong financial results and raised guidance, signals management's optimistic outlook for Catalyst's continued growth. Investors responded positively to these developments, as reflected in the significant after-hours stock price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Catalyst Pharmaceuticals Soars 6.36% After Hours on Strong Q3 Results, Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Catalyst Pharmaceuticals Soars 6.36% After Hours on Strong Q3 Results, Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 06:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Catalyst Pharmaceuticals (CPRX) jumped 6.36% in after-hours trading on Wednesday following the company's release of better-than-expected third-quarter results and an increase in full-year guidance. The biopharmaceutical firm, which focuses on developing and commercializing therapies for people with rare diseases, demonstrated strong financial performance driven by its key products.</p>\n\n<p>Catalyst reported Q3 revenue of $148.40 million, significantly beating analyst estimates of $136.80 million. The company's flagship product, FIRDAPSE, continued to show sustained organic growth and market penetration, while AGAMREE also contributed to the revenue growth with strong demand and penetration into Duchenne Muscular Dystrophy (DMD) centers. In light of these positive results, Catalyst raised its full-year 2025 revenue guidance to $565-$585 million, up from previous estimates.</p>\n\n<p>The company's confidence in its future prospects was further underscored by the announcement of a $200 million share repurchase program. This move, coupled with the strong financial results and raised guidance, signals management's optimistic outlook for Catalyst's continued growth. Investors responded positively to these developments, as reflected in the significant after-hours stock price increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPRX","symbol_name":"Catalyst Pharmaceutical Partners","start_time":0,"source_url":"","article_id":"1179410063","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179410063","pubTimestamp":1762380545,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Catalyst Pharmaceuticals (CPRX) jumped 6.36% in after-hours trading on Wednesday following the company's release of better-than-expected third-quarter results and an increase in full-year...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CPRX":"Catalyst Pharmaceutical Partners"},"translate_title":"个股赛道|Catalyst Pharmaceuticals盘后大涨6.36%Q3业绩强劲上调指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":1},"content_text":"Shares of Catalyst Pharmaceuticals (CPRX) jumped 6.36% in after-hours trading on Wednesday following the company's release of better-than-expected third-quarter results and an increase in full-year guidance. The biopharmaceutical firm, which focuses on developing and commercializing therapies for people with rare diseases, demonstrated strong financial performance driven by its key products.\nCatalyst reported Q3 revenue of $148.40 million, significantly beating analyst estimates of $136.80 million. The company's flagship product, FIRDAPSE, continued to show sustained organic growth and market penetration, while AGAMREE also contributed to the revenue growth with strong demand and penetration into Duchenne Muscular Dystrophy (DMD) centers. In light of these positive results, Catalyst raised its full-year 2025 revenue guidance to $565-$585 million, up from previous estimates.\nThe company's confidence in its future prospects was further underscored by the announcement of a $200 million share repurchase program. This move, coupled with the strong financial results and raised guidance, signals management's optimistic outlook for Catalyst's continued growth. Investors responded positively to these developments, as reflected in the significant after-hours stock price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179410063","isCrawlerRequest":true}